Spirogen Ltd.
Spirogen was founded to commercialize a platform technology capable of discovering lead compounds that target any gene sequence. The company’s work has led to novel toxic anticancer therapeutics for use in antibody drug conjugates (ADCs).
Investors
Cambridge Research BioVentures Ltd. (CRB), backed by Research Corporation Technologies, was the lead investor in Spirogen Ltd. Other investors include Cambridge Research & Innovation Ltd. (CRIL), Xenva Ltd. and Bloomsbury Investment Capital.
Inventors/Founders
- Prof. David Thurston
University of Nottingham - Philip Howard, Ph.D.
University of Nottingham - John Hartley, Ph.D.
University College London